Cargando…

Recent Strategic Advances in CFTR Drug Discovery: An Overview

Cystic fibrosis transmembrane conductance regulator (CFTR)-rescuing drugs have already transformed cystic fibrosis (CF) from a fatal disease to a treatable chronic condition. However, new-generation drugs able to bind CFTR with higher specificity/affinity and to exert stronger therapeutic benefits a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusnati, Marco, D’Ursi, Pasqualina, Pedemonte, Nicoletta, Urbinati, Chiara, Ford, Robert C., Cichero, Elena, Uggeri, Matteo, Orro, Alessandro, Fossa, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177952/
https://www.ncbi.nlm.nih.gov/pubmed/32244346
http://dx.doi.org/10.3390/ijms21072407
_version_ 1783525342739169280
author Rusnati, Marco
D’Ursi, Pasqualina
Pedemonte, Nicoletta
Urbinati, Chiara
Ford, Robert C.
Cichero, Elena
Uggeri, Matteo
Orro, Alessandro
Fossa, Paola
author_facet Rusnati, Marco
D’Ursi, Pasqualina
Pedemonte, Nicoletta
Urbinati, Chiara
Ford, Robert C.
Cichero, Elena
Uggeri, Matteo
Orro, Alessandro
Fossa, Paola
author_sort Rusnati, Marco
collection PubMed
description Cystic fibrosis transmembrane conductance regulator (CFTR)-rescuing drugs have already transformed cystic fibrosis (CF) from a fatal disease to a treatable chronic condition. However, new-generation drugs able to bind CFTR with higher specificity/affinity and to exert stronger therapeutic benefits and fewer side effects are still awaited. Computational methods and biosensors have become indispensable tools in the process of drug discovery for many important human pathologies. Instead, they have been used only piecemeal in CF so far, calling for their appropriate integration with well-tried CF biochemical and cell-based models to speed up the discovery of new CFTR-rescuing drugs. This review will give an overview of the available structures and computational models of CFTR and of the biosensors, biochemical and cell-based assays already used in CF-oriented studies. It will also give the reader some insights about how to integrate these tools as to improve the efficiency of the drug discovery process targeted to CFTR.
format Online
Article
Text
id pubmed-7177952
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71779522020-04-28 Recent Strategic Advances in CFTR Drug Discovery: An Overview Rusnati, Marco D’Ursi, Pasqualina Pedemonte, Nicoletta Urbinati, Chiara Ford, Robert C. Cichero, Elena Uggeri, Matteo Orro, Alessandro Fossa, Paola Int J Mol Sci Review Cystic fibrosis transmembrane conductance regulator (CFTR)-rescuing drugs have already transformed cystic fibrosis (CF) from a fatal disease to a treatable chronic condition. However, new-generation drugs able to bind CFTR with higher specificity/affinity and to exert stronger therapeutic benefits and fewer side effects are still awaited. Computational methods and biosensors have become indispensable tools in the process of drug discovery for many important human pathologies. Instead, they have been used only piecemeal in CF so far, calling for their appropriate integration with well-tried CF biochemical and cell-based models to speed up the discovery of new CFTR-rescuing drugs. This review will give an overview of the available structures and computational models of CFTR and of the biosensors, biochemical and cell-based assays already used in CF-oriented studies. It will also give the reader some insights about how to integrate these tools as to improve the efficiency of the drug discovery process targeted to CFTR. MDPI 2020-03-31 /pmc/articles/PMC7177952/ /pubmed/32244346 http://dx.doi.org/10.3390/ijms21072407 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rusnati, Marco
D’Ursi, Pasqualina
Pedemonte, Nicoletta
Urbinati, Chiara
Ford, Robert C.
Cichero, Elena
Uggeri, Matteo
Orro, Alessandro
Fossa, Paola
Recent Strategic Advances in CFTR Drug Discovery: An Overview
title Recent Strategic Advances in CFTR Drug Discovery: An Overview
title_full Recent Strategic Advances in CFTR Drug Discovery: An Overview
title_fullStr Recent Strategic Advances in CFTR Drug Discovery: An Overview
title_full_unstemmed Recent Strategic Advances in CFTR Drug Discovery: An Overview
title_short Recent Strategic Advances in CFTR Drug Discovery: An Overview
title_sort recent strategic advances in cftr drug discovery: an overview
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177952/
https://www.ncbi.nlm.nih.gov/pubmed/32244346
http://dx.doi.org/10.3390/ijms21072407
work_keys_str_mv AT rusnatimarco recentstrategicadvancesincftrdrugdiscoveryanoverview
AT dursipasqualina recentstrategicadvancesincftrdrugdiscoveryanoverview
AT pedemontenicoletta recentstrategicadvancesincftrdrugdiscoveryanoverview
AT urbinatichiara recentstrategicadvancesincftrdrugdiscoveryanoverview
AT fordrobertc recentstrategicadvancesincftrdrugdiscoveryanoverview
AT cicheroelena recentstrategicadvancesincftrdrugdiscoveryanoverview
AT uggerimatteo recentstrategicadvancesincftrdrugdiscoveryanoverview
AT orroalessandro recentstrategicadvancesincftrdrugdiscoveryanoverview
AT fossapaola recentstrategicadvancesincftrdrugdiscoveryanoverview